PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

indapamide Side Effects

The reactions most often reported to the FDA for indapamide (also sold as Lozol), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

17,199
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 2004 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of indapamide come from 17,199 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 17,199 reports to the FDA Adverse Event Reporting System (FAERS) for indapamide (Lozol): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

17,199

Reports Mentioning Death

1,091

6.3% of reports — not proof the medicine caused the death

Hospitalizations

8,087

47.0% of reports

Top Indication

Product Used For Unknown Indication

Most Reported Adverse Reactions

HYPONATRAEMIA
1,286
ACUTE KIDNEY INJURY
925
DYSPNOEA
898
DIZZINESS
875
NAUSEA
863
DIARRHOEA
843
FATIGUE
781
DRUG INTERACTION
756
HYPOKALAEMIA
746
VOMITING
699
MALAISE
695
FALL
652
HEADACHE
640
ASTHENIA
639
ARTHRALGIA
608
HYPOTENSION
597
CONFUSIONAL STATE
571
COUGH
564

Who Reports Side Effects

Gender Distribution

Female 9,087 (58%)
Male 6,696 (42%)
Unknown 19

Age Distribution

0-17 78 (1%)
18-44 605 (4%)
45-64 4,127 (30%)
65-74 4,429 (32%)
75+ 4,518 (33%)

Reporting Trend by Year

2004 2025

Reactions in Death Reports

Top reactions reported in 1,091 reports where death was an outcome. These are voluntarily reported and do not establish causation.

Reaction Reports
DEATH 194
ACUTE KIDNEY INJURY 86
DIARRHOEA 70
CARDIAC ARREST 61
PNEUMONIA 61
VOMITING 52
DYSPNOEA 49
LACTIC ACIDOSIS 48
FALL 45
RENAL FAILURE 45
ANAEMIA 42
SEPSIS 41
FATIGUE 39
MALAISE 38
MYOCARDIAL INFARCTION 38
NAUSEA 37
ABDOMINAL PAIN 35
ACUTE RESPIRATORY DISTRESS SYNDROME 35
HYPERTENSION 35
INTERSTITIAL LUNG DISEASE 35

Reactions in Hospitalization Reports

Top reactions in 8,087 reports where hospitalization was an outcome.

Reaction Reports
HYPONATRAEMIA 1,110
ACUTE KIDNEY INJURY 671
HYPOKALAEMIA 568
DYSPNOEA 498
VOMITING 492
FALL 477
DRUG INTERACTION 456
DIARRHOEA 437
NAUSEA 426
CONFUSIONAL STATE 424
HYPOTENSION 417
DIZZINESS 403
MALAISE 379
ASTHENIA 365
FATIGUE 332
PNEUMONIA 313
PYREXIA 303
ABDOMINAL PAIN 295
DEHYDRATION 291
ATRIAL FIBRILLATION 287

Compare indapamide vs acebutolol →

What the FAERS Data Reveals About indapamide Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 17,199 voluntary reports linked to indapamide and its brand equivalents (Lozol), spanning 2004 through 2025. Of those, 1,091 (6.3%) listed death as an outcome and 8,087 (47.0%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 58% were female and 42% male; age distribution skews toward 75+, with 4,518 reports in that bracket. The single most reported reaction is hyponatraemia with 1,286 submissions, followed by acute kidney injury and dyspnoea.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.